Pharmaceuticals, Biotechnology & Life Sciences

Skinbiotherapeutics PLC unveils new audit chair and external probe to boost governance and financial transparency amid market volatility.

OSE Immuno shifts focus to chronic pouchitis and hidradenitis suppurativa with Lusvertikimab amid volatile stock and negative earnings, exploring a risky yet promising niche in biotech.

Explore how Bayer AG’s 2026 stock performance and brand value are linked to its football club’s Bundesliga results, and discover strategies to protect investor confidence.

Tonix Pharmaceuticals focuses on CNS disorders, with Phase 3 data on TONMYA™ for fibromyalgia and PTSD, while its stock reflects the volatile biotech market and investor hopes for breakthrough therapies.

Ardelyx’s Q4 results show a revenue beat but earnings miss, hurting stock despite a $1 billion 2029 goal for Ibsrela and new pipeline expansion.

Vanda Pharmaceuticals’ FDA approval of BYSANTI (milsaperidone) for bipolar I and schizophrenia marks a strategic breakthrough, promising a strong exclusivity window, premium pricing, and significant investor upside.

Explore MannKind’s biopharma strategy, stock performance, and innovation pipeline in diabetes, cancer, and autoimmune therapy markets.

OSR Holdings Inc, a Nasdaq‑listed healthcare blank‑check firm, faces volatility as its stock lingers near a $0.432 low, a negative P/E and low P/B reflect current financial struggles, while strategic acquisition plans drive its future growth potenti…

Avant Brands Inc. on TSX: cannabis‑maker struggling with a negative P/E and low P/B, a recent shareholder‑rights plan, and modest 52‑week highs/lows – insights on its restructuring prospects.

CDT Equity’s $115 M stake in AI firm Sarborg and new election‑cybersecurity initiative show San Diego‑based life‑science company expanding beyond healthcare into tech‑driven growth.